HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $90 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Viking Therapeutics (NASDAQ:VKTX) and maintained a $90 price target, as stated by analyst Joseph Pantginis.
July 25, 2024 | 12:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Viking Therapeutics and maintained a $90 price target, indicating strong confidence in the company's future performance.
The reiteration of a Buy rating and a high price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100